Hi, what are you looking for?
By Helena Smolak
Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for patients with atrial fibrillation due to lack of efficacy.
The German pharmaceutical-and-agricultural group said late Sunday that the decision is based on a recommendation by the independent…
Read the full article here
Follow Play Earnings CallPlay Earnings Call Riot Platforms, Inc. (RIOT) Discusses Transformational Milestones and Strategic Data Center Expansion January 16, 2026 10:00 AM EST...
This article was written by Follow Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various...
